Evidence map›Paper›PMID 32448808›Full record

Trial reportInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2020

Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial.

Victor Lago, Pilar Bello, Beatriz Montero, Luis Matute, Pablo Padilla-Iserte, Susana Lopez, Tiermes Marina, Marc Agudelo, Santiago Domingo

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 5 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03452982 phase2completednot on this map

Sentinel Lymph Node in Early Ovarian Cancer

TypeinterventionalSponsorInstituto de Investigacion Sanitaria La FeRan2018 to 2019Enrolled20ConditionsOvarian CancerArmssentinel node technique
NCT05927818 narecruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy of Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer

TypeinterventionalSponsorIstanbul UniversityRan2023 to 2026Enrolled100ConditionsSentinel Lymph Node, Ovarian CarcinomaArmsSentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Molecular image-guided surgery in gynaecological cancer: where do we stand?European journal of nuclear medicine and molecular imaging · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. short review of current implementations of sentinel lymph node mapping in gynecologic cancersJournal of the Turkish German Gynecological Association · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Victor LagoGynecologic Oncology Department, University Hospital La Fe, Valencia, Spain victor.lago.leal@hotmail.com.
Pilar BelloNuclear Medicine Department, University Hospital La Fe, Valencia, Spain.
Beatriz MonteroPathology Department, University Hospital La Fe, Valencia, Spain.
Luis MatuteGynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.
Pablo Padilla-IserteGynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.
Susana LopezPathology Department, University Hospital La Fe, Valencia, Spain.
Tiermes MarinaGynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.
Marc AgudeloNuclear Medicine Department, University Hospital La Fe, Valencia, Spain.
Santiago DomingoGynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.
Hospital Universitari i Politècnic La Fe · ESInstituto de Investigación Sanitaria La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEarly-stage ovarian cancer might represent an ideal disease scenario for sentinel lymph node application. Nevertheless, the published experience seems to be limited. Our objective was to assess the feasibility and safety concerns of sentinel lymph node biopsy in patients with clinical stage I-II ovarian cancer.

methodsWe conducted a prospective cohort study of 20 patients with histologically confirmed ovarian cancer.

resultsA total of 20 patients were included in the analysis. Sentinel lymph nodes were detected in 14/15 (93%) pelvic and all 20 (100%) para-aortic regions. Five patients did not have utero-ovarian injection because of prior hysterectomy. The mean time from injection to sentinel lymph node resection was 53±15 min (range; 30-80). The mean number of harvested sentinel lymph nodes was 2.2±1.5 (range; 0-5) lymph nodes in the pelvis and 3.3±1.8 (range; 1-7) lymph nodes in the para-aortic region. There were no adverse intraoperative events, nor any within the 30 days of follow-up related with the technique.

conclusionSentinel lymph node mapping in early-stage ovarian cancer is feasible without major intraoperative or < 30 days safety concerns. (NCT03452982). TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT03452982.

Indexed as

Cohort StudiesFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsProspective StudiesSentinel Lymph NodeSentinel Lymph Node Biopsyovarian cancersentinel lymph nodesurgical oncology

Identifiers

PMID32448808
PMCPMC7497563
OpenAlexW3026629953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.